Stocktoria

Sionna Therapeutics, Inc. SION

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2025-02-07

Sionna Therapeutics, Inc. financials (annual)

Revenue
20242025
Net income
-$61.7M -$75.3M 20242025
Free cash flow
-$52.8M -$66.7M 20242025

Bars are annual figures from 2024 to 2025; red bars are negative (a loss or cash outflow).

MetricFY2025FY2024
R&D expense$60.3M$57.3M
Operating income-$89.0M-$70.6M
Income tax$0$0
Net income-$75.3M-$61.7M
EPS (diluted)$-1.88$-15.99
Operating cash flow-$66.3M-$52.8M
Free cash flow-$66.7M-$52.8M
Cash & equivalents$58.5M$37.8M
Total assets$326.0M$185.8M
Total liabilities$19.1M$19.1M
Shareholders' equity$306.8M-$163.7M

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.